NIH Funding Opportunities

Notice of NIAMS Withdrawal from Participation inPAR-19-173 "Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)"
Notice NOT-AR-21-027 from the NIH Guide for Grants and Contracts
Tue, 27 Jul 2021 12:00:56 EST

Notice of Correction to RFA-DA-22-032, HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed).
Notice NOT-DA-21-067 from the NIH Guide for Grants and Contracts
Wed, 28 Jul 2021 11:15:32 EST

Notice of Correction to Effort Requirements Identified in NOT-DK-21-018 for PAR-20-220: Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C Clinical Trial Not Allowed)
Notice NOT-DK-21-026 from the NIH Guide for Grants and Contracts
Wed, 28 Jul 2021 10:41:00 EST

Notice of Special Interest: Administrative Supplements for RCMI Practice-Based Clinical Research Networks
Notice NOT-MD-21-025 from the NIH Guide for Grants and Contracts
Wed, 28 Jul 2021 10:35:13 EST

Updated Policy for Family Leave and Unpaid Leave for Extramural Loan Repayment Program Recipients
Notice NOT-OD-21-153 from the NIH Guide for Grants and Contracts
Mon, 26 Jul 2021 11:14:42 EST

Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-21-041 from the NIH Guide for Grants and Contracts. Cut and paste
Mon, 26 Jul 2021 11:12:28 EST

Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-21-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the U01 PDAC Stromal Reprogramming Consortium (PSRC) RFA-CA-21-041. The purpose of this FOA is to create a U24 Coordinating and Data Management Center (CDMC) that will support the overall coordination and research aims of the PSRC Research Projects. This FOA solicits U24 cooperative agreement applications from appropriate multidisciplinary groups that can assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative and data management activities of the PSRC. This FOA is open to any qualified applicant.
Mon, 26 Jul 2021 11:13:01 EST

Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-21-050 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051).
Tue, 27 Jul 2021 12:09:47 EST

Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-21-051 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support a coordinating center to facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN; see U01 awards supported under companion RFA-CA-21-050) that will conduct immunotherapy clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials. The network will include a representative from the NCI Comparative Oncology Program (COP) of the NCI's Center for Cancer Research as an integral component. The awardee will contribute to the administration of a steering committee of required expertise--both inside and outside the U01 network, including the PD/PIs of the U01s, representatives of the COP, and the NCI Project Collaborators --to ensure that the goals of the network are accomplished. The Coordinating Center will have several responsibilities, including, but not limited to providing administrative support to the K9CIN: development and standardization of clinical protocols and correlative assays; implementation of clinical studies in immunotherapy and combination agents including accrual to the trials; providing statistical support; facilitating sharing of agents, specimens, and data; harmonization of clinical data; and submission of clinical and correlative data to the Integrated Canine Data Commons.
Tue, 27 Jul 2021 12:09:46 EST

Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus (R01 Clinical Trial Required)
Funding Opportunity RFA-DK-21-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials of interventions designed to improve technology adoption in individuals from underrepresented backgrounds with type 1 diabetes mellitus (T1D). Through successful execution, these pilot and feasibility trials should provide feasibility data for larger, pragmatic trials with the overarching goal of reducing health disparity in T1D through improving technology usage in individuals from minority racial and ethnic backgrounds.
Wed, 28 Jul 2021 12:54:16 EST

BRAIN Initiative Cell Atlas Network (BICAN): Comprehensive Center on Human and Non-human Primate Brain Cell Atlases (UM1 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-21-235 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. The Centers are expected to characterize all brain cell types (neurons, glia, and other non-neuronal cells) at high-resolution. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.
Tue, 27 Jul 2021 12:24:24 EST

BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-21-236 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BICAN projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.
Tue, 27 Jul 2021 12:24:26 EST

BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-21-237 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) that will be composed of four components to establish respectively (1) a common sequencing data processing pipeline, (2) a common imaging data processing pipeline, (3) a comprehensive brain cell knowledge base, and (4) an engaging and outreach component to coordinate the research within and beyond BICAN. The overall goals of CUBIE are to (i) enable the exploration of large-scale brain cell atlas data and knowledge, and inspire research in brain function and disorders; and (ii) ensure research rigor and data reproducibility by making the data to be findable, accessible, interoperable, and reusable, and the process transparent. An application is expected to propose only one of the above four respective components.
Tue, 27 Jul 2021 12:25:14 EST

Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
Funding Opportunity PAR-21-288 from the NIH Guide for Grants and Contracts. Reissue of RFA-20-351.The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.
Wed, 28 Jul 2021 12:49:45 EST

Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
Funding Opportunity PAR-21-289 from the NIH Guide for Grants and Contracts. Reissue of RFA-20-350. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.
Wed, 28 Jul 2021 12:49:43 EST